Soft tissue sarcoma: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 2, 2005, Pages 158-194

  Demetri, George D ^a   Baker, Laurence H ^b   Beech, Derrick ^c   Benjamin, Robert ^d   Casper, Ephraim S ^e   Conrad III, Ernest U ^f   DeLaney, Thomas F ^a   Ettinger, David S ^g   Heslin, Martin J ^h   Hutchinson, Ray J ^b   Kiel, Krystyna ⁱ   Kraybill, William G ^j   Letson, G Douglas ^k   Neff, James ^l   O'Donnell, Richard J ^m   Paz, I Benjamin ⁿ   Pollock, Raphael E ^d   Randall, R Lor ^o   Schupak, Karen D ^e   Tyler, Douglas S ^p   Von Mehren, Margaret ^q   Wayne, Jeffrey ⁱ   more..

^a Dana Farber/Partners CancerCare   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f SEATTLE CANCER CARE ALLIANCE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l NEBRASKA MEDICAL CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ City of Hope Cancer Center   (United States)

^o UNIVERSITY OF UTAH   (United States)

^p DUKE CANCER INSTITUTE   (United States)

^q FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

Chemotherapy; Desmoid tumor; Gastrointestinal stromal tumors; NCCN Clinical Practice Guidelines; Radiation therapy; Retroperitoneal sarcomas; Soft tissue extremity sarcoma; Soft tissue sarcoma; Surgery

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; IRINOTECAN; MESNA; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOIC ACID; SULINDAC; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TOREMIFENE; TRABECTEDIN; VINBLASTINE;

ANGIOSARCOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHEMOEMBOLIZATION; CLINICAL TRIAL; CRYOTHERAPY; DESMOID TUMOR; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PRACTICE GUIDELINE; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; RADIOTHERAPY; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 33747614793     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94-109.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. Pisters P. Staging and prognosis. In: Pollock RE, ed. American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamilton, Ontario: BC Decker; 2002:80-88.
4. Kindblom LG, Meis-Kindblom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)-a population-based study of 600 cases (Abstr #5770). Ann Oncol 2002;13:157.
5. Fletcher C, Berman J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465.
6. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-514.
7. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histiologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
8. Greene FL, Page DL, Fleming ID, et al (eds). AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002.
9. National Institute of Health consensus development panel on limb-sparing treatment of adult soft tissue sarcoma and osteosarcomas. Proceedings of Cancer Treatment Symposium, 1985:1-5.
10. Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981;47:2391-2397.
11. Yang JC, Chang AE, Baker AR, et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
12. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-868.
13. Clasby R, Tilling K, Smith MA, et al. Variable management of soft tissue sarcoma: Regional audit with implications for specialist care. Br J Surg 1997;84:1692-1696.
14. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am 1999;8:91-107.
15. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988;150:615-620.
16. Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:629-650.
17. Geer RJ, Woodruff J, Casper ES, et al. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127:1285-1289.
18. Karakousis CP, Emrich LJ, Rao U, et al. Limb salvage in soft tissue sarcomas with selective combination of modalities. Eur J Surg Oncol 1991;17:71-80.
19. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin Surg Oncol 1994;10:347-356.
20. Barkley HT, Martin RG, Romsdahl MM, et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Rad Oncol Biol Phys 1988;14:693-699.
21. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746-751.
22. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:819.
23. Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-4477.
24. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17:3252-3259.
25. Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000:CD001419.
26. Pisters PWT, Patel SR, Varma DGK, et al. Preoperative chemotherapy for stage IUB extremity soft tissue sarcoma: Long-term results from a single institution. J Clin Oncol 1997;15:3481-3487.
27. Spiro IJ, Gebhardt MC, Jennings LC, et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997;24:540-546.
28. Rosenberg SA, Tepper JE, Glatstein EJ, et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-315.
29. Alektiar KM, Velasco J, Zelefsky MJ, et al. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2000;48:1051-1058.
30. Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230.
31. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol 2002;9:48-56.
32. Bramwell VHC, Rouesse J, Steward W, et al. Adjuvant CY-VADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-1149.
33. Tierney JF. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 1997;350:1647-1654.
34. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.
35. Deckert PM, Siehl JM, Thiel E, et al. Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22(suppl 14):9011.
36. Lindner LH, Schlemmer M, Hohenberger P, et al. First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:821.
37. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998;21:317-321.
38. Meric F, Hess KR, Varma DG, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95:1120-1126.
39. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002;9:535-542.
40. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectahle leiomyosarcoma: results of a phase 11 trial. J Clin Oncol 2002;20:2824-2831.
41. Leu KM, Ostruszka LJ, Schewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-1712.
42. Lewis JJ, Leung DHY, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 1999;134:199-194.
43. Fleming JB, Cantor SB, Varma DG, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 2001;92:863-868.
44. Porter GA, Cantor SB, Ahmad SA, et al. Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas. Cancer 2002;94:197-204.
45. Singer S, Antman KH, Corson JM, et al. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992;127:548-553.
46. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490.
47. Samuels BL, Rushing D, Chawla SP, et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:818.
48. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899.
49. Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995;221:185-195.
50. Lewis JJ, Leung DHY, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355-365.
51. Jaques DP, Coit DG, Hajdu SI, et al. Management of primary and recurrent soft tissue sarcoma of the retroperitoneum. Ann Surg 1990;212:51-59.
52. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
53. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-1216.
54. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-87.
55. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
56. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995;75:154-170.
57. Goss GA, Merriam P, Manola J, et al. Clinical and pathological characteristics of gastrointestinal stromal tumors (GISTs) (abstract). Proc Am Soc Clin Oncol 2000;19:559a.
58. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
59. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
60. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033 (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:819.
61. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
62. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 2004;364:1127-1134.
63. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-475.
64. Demetri GD, Benjamin R, Blanke CD, et al. NCCN Task Force Report: Optimal management of patients with gastrointestinal stromal tumor (GIST)-Expansion and Update of NCCN Clinical Practice Guidelines. JNCCN 2004;2 (suppl):S1-S26.
65. Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning (abstract). 2004 ASCO Proceedings (post-meeting edition). J Clin Oncol 2004;22:198.
66. Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:195.
67. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 2003;97:1134-1135.
68. Scott RJ, Froggatt NJ, Trembath RC, et al. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3′ APC gene mutation. Hum Mol Genet 1996;5:1921-1924.
69. Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001;48:515-521.
70. Pignatti G, Barbanti-Brodano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop 2000;375:207-213.
71. Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor. Not a benign disease. Arch Surg 1989;124:191-196.
72. Sorensen A, Keller J, Nielsen OS, et al. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. Acta Orthop Scand 2002;73:213-219.
73. Biermann JS. Desmoid tumors. Curr Treat Options Oncol 2000;1:262-266.
74. Godwin Y, McCulloch TA, Sully L. Extra-abdominal desmoid tumour of the breast: review of the primary management and the implications for breast reconstruction. Br J Plast Surg 2001;54:268-271.
75. Yamaguchi H, Sakakibara T, Hino M, et al. A case of fibromatosis of the breast. Breast Cancer 2002;9:175-178.
76. Kouriefs C, Leris AC, Mokbel K, et al. Infiltrating fibromatosis of the breast: a potential pitfall. Int J Clin Pract 2002;56:401-402.
77. Pritchard DJ, Nascimento AG, Petersen IA, et al. Local control of extra-abdominal desmoid tumors. J Bone Joint Surg Am 1996;78:848-854.
78. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-167.
79. Stojadinovic A, Hoos A, Karpoff HM, et al. Soft tissue tumors of the abdominal wall. Analysis of disease patterns and treatment. Arch Surg 2001;136:70-79.
80. Baker LH, Wathen K, Chugh R, et al. Activity of imatinib mesylate in desmoid tumors: interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:821.
81. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390-1397.
82. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg 1999;229:866-872.
83. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998;42:1007-1014.
84. Schulz-Ertner D, Zierhut D, Mende U, et al. The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol 2002;178:78-83.
85. Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer 1984;54:2051-2055.
86. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181-190.
87. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer 1991;68:1384-1388.
88. Thomas S, Datta-Gupta S, Kapur BM. Treatment of recurrent desmoid tumor with tamoxifen. Aust N Z J Surg 1990;60:919-921.
89. Izes JK, Zinman LN, Larsen CR. Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 1996;47:756-759.
90. Waddell WR, Gerner RE, Reich MP. Nonsteroid anti-inflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 1983;22:197-211.
91. Lackner H, Urban C, Kerbl R, et al. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 1997;80:334-340.
92. Kyasa MJ. Phase II trial of tamoxifen and interferon alpha in patients with metastatic or recurrent soft tissue sarcoma (abstract). 2004 ASCO Annual Meeting Proceedings (post-meeting edition). J Clin Oncol 2004;22:825.
93. Chao AS, Lai CH, Hsueh S, et al. Successful treatment of recurrent pelvic desmoid tumour with tamoxifen: case report. Hum Reprod 2000;15:311-313.
94. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-620.
95. Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol 2000;73:21-25.
96. Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-2379.
97. Skapek SX, Hawk BJ, Hoffer FA, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children [see comments]. J Clin Oncol 1998;16:3021-3027.
98. Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. Cancer 1993;71:2242-2244.
99. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72:3244-3247.
100. Lynch HT, Fitzgibbons R, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994;37:260-267.
101. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989;64:1192-1194.
102. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine [published erratum appears in Am J Clin Oncol 1999;22:193-195.